Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia

Zhongzheng Li,Xin Liu,Lan Wang,Huabin Zhao,Shenghui Wang,Guoying Yu,Depei Wu,Jianhong Chu,Jingjing Han

DOI: https://doi.org/10.3389/fimmu.2023.1281687

IF: 7.3

2023-10-31

Frontiers in Immunology

Abstract:Introduction Acute myeloid leukemia (AML) is a type of blood cancer that is identified by the unrestricted growth of immature myeloid cells within the bone marrow. Despite therapeutic advances, AML prognosis remains highly variable, and there is a lack of biomarkers for customizing treatment. RNA N6-methyladenosine (m 6 A) modification is a reversible and dynamic process that plays a critical role in cancer progression and drug resistance. Methods To investigate the m 6 A modification patterns in AML and their potential clinical significance, we used the AUCell method to describe the m 6 A modification activity of cells in AML patients based on 23 m 6 A modification enzymes and further integrated with bulk RNA-seq data. Results We found that m 6 A modification was more effective in leukemic cells than in immune cells and induced significant changes in gene expression in leukemic cells rather than immune cells. Furthermore, network analysis revealed a correlation between transcription factor activation and the m 6 A modification status in leukemia cells, while active m 6 A-modified immune cells exhibited a higher interaction density in their gene regulatory networks. Hierarchical clustering based on m 6 A-related genes identified three distinct AML subtypes. The immune dysregulation subtype, characterized by RUNX1 mutation and KMT2A copy number variation, was associated with a worse prognosis and exhibited a specific gene expression pattern with high expression level of IGF2BP3 and FMR1 , and low expression level of ELAVL1 and YTHDF2 . Notably, patients with the immune dysregulation subtype were sensitive to immunotherapy and chemotherapy. Discussion Collectively, our findings suggest that m 6 A modification could be a potential therapeutic target for AML, and the identified subtypes could guide personalized therapy.

immunology